{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:04:35Z","timestamp":1785539075481,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semarthrit.2024.152504","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T15:36:54Z","timestamp":1719675414000},"page":"152504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-027X","authenticated-orcid":false,"given":"Dimitrios A","family":"Pappas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152504_bib0001","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0002","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation","volume":"68","author":"van Halm","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0003","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.23548","article-title":"Causes of death in rheumatoid arthritis: how do they compare to the general population?","volume":"70","author":"Widdifield","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0004","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0005","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \u2018high-grade\u2019 systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0006","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0007","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0008","doi-asserted-by":"crossref","first-page":"730.e9","DOI":"10.1016\/j.amjmed.2013.02.016","article-title":"Cardiovascular risk in rheumatoid arthritis: comparing TNF-\u03b1 blockade with nonbiologic DMARDs","volume":"126","author":"Solomon","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0009","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0010","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.a","volume":"45","author":"Khovidhunkit","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0011","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0012","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1136\/ard.2006.066191","article-title":"Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis","volume":"66","author":"Popa","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0013","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2006.059691","article-title":"Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis","volume":"66","author":"Peters","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0014","first-page":"446","article-title":"Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience","volume":"27","author":"Schimmel","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tcm.2016.07.006","article-title":"Cardiovascular disease in patients with rheumatoid arthritis","volume":"27","author":"Liao","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0016","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","article-title":"Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis","volume":"110","author":"Crowson","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0017","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2013-204024","article-title":"Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0018","first-page":"S96","article-title":"The Corrona US registry of rheumatic and autoimmune diseases","volume":"34","author":"Kremer","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2474-15-113","article-title":"Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients","volume":"15","author":"Pappas","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","article-title":"Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis","volume":"110","author":"Crowson","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0021","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men","volume":"118","author":"Ridker","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0022","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/216507990805600407","article-title":"The Reynolds Risk Score\u2013improving cardiovascular risk prediction in women","volume":"56","author":"Bassuk","year":"2008","journal-title":"AAOHN J"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0023","article-title":"General cardiovascular risk profile for use in primary care: the Framingham heart study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0024","series-title":"Applied multiple regression \/Correlation analysis for the behavioral sciences","author":"Cohen","year":"1983"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0025","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation","volume":"68","author":"van Halm","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0026","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0027","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0028","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tcm.2016.07.006","article-title":"Cardiovascular disease in patients with rheumatoid arthritis","volume":"27","author":"Liao","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0029","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0030","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British society for rheumatology biologics register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0031","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0032","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0033","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2013-204024","article-title":"Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0034","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220178","article-title":"Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis","volume":"14","author":"Castagn\u00e9","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0036","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0037","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0038","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0039","doi-asserted-by":"crossref","unstructured":"39.Sacks F.M. & Ridker P.M. Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Herz 24, 51\u20136 (1999).","DOI":"10.1007\/BF03043818"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0040","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0041","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-128-2-199801150-00009","article-title":"The pathophysiologic roles of interleukin-6 in human disease","volume":"128","author":"Papanicolaou","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0042","doi-asserted-by":"crossref","first-page":"e30563","DOI":"10.1097\/MD.0000000000030563","article-title":"Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: a systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Yang","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0043","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/acr.22377","article-title":"Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research","volume":"66","author":"Curtis","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0044","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3899\/jrheum.121507","article-title":"Cholesteryl ester transfer protein in patients with rheumatoid arthritis","volume":"40","author":"Ferraz-Amaro","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0046","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001588","article-title":"The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis","volume":"4","author":"Liao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.semarthrit.2024.152504_bib0047","unstructured":"47.Razmjou A. et al. Disease response in rheumatoid arthritis across 4 biologic therapies associates with improvement in paraoxonase-1 activity. ACR convergence Preprint at https:\/\/acrabstracts.org\/abstract\/diseaseresponseinrheumatoidarthritisacross4biologictherapiesassociateswithimprovement-in-paraoxonase-1-activity\/(2022)."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:14:08Z","timestamp":1726618448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":47,"alternative-id":["S0049017224001446"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152504","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152504"}}